Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Order: Signal: Tickers:
Overview Valuation Financial Ownership Performance Technical Custom Charts Tickers Quotes Basic TA News Snapshot
Total: 1 #1
TickerAZN [NYSE]
CompanyAstraZeneca PLC
CountryUnited Kingdom
IndustryDrug Manufacturers - Major
Market Cap90.71BEPS (ttm)0.81
P/E88.51EPS this Y-58.70%
Forward P/E16.97EPS next Y-4.74%
PEG88.51EPS past 5Y-13.40%
P/S3.45EPS next 5Y1.00%
P/B4.43EPS Q/Q-79.80%
Dividend2.51%Sales Q/Q4.70%
Insider Own-Inst Own6.70%
Insider Trans-Inst Trans-15.48%
Short Float0.41%EarningsJan 27/b
Analyst Recom2.50Target Price78.73
Avg Volume2.05M52W Range55.93 - 81.61
Dec-19-14 02:39PMAstraZeneca cancer drug, companion test approved AP
Dec-18-14 06:44AM6:44 am AstraZeneca announced that the EC has granted Marketing Authorization for Lynparza as a first-in-class treatment for advanced BRCA-mutated ovarian cancer Briefing.com
Dec-11-14 08:10PMThe Big Business of Selling Prescription-Drug Records at BusinessWeek
Dec-11-14 04:01PMAmgen And AstraZeneca To Present Results From Phase 3 AMAGINE-1 Study Evaluating Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis PR Newswire
Dec-10-14 05:50PMNektar/AstraZeneca's Moventig Gets EU Approval for OIC Zacks
Dec-10-14 12:41PMDrug makers face another $65 billion patent cliff at MarketWatch
Dec-10-14 11:04AMMerck's Keytruda Might Treat Virulent Breast Cancer at Investor's Business Daily
Dec-10-14 10:22AM6 ugly stocks that look sexy in 2015 at CNNMoney.com
Dec-09-14 05:20PMDynavax & AstraZeneca Alter Agreement for Asthma Product Zacks
Dec-08-14 05:30PMActavis' Antibiotic Backed for FDA Approval, Response in Q1 Zacks
1